Duration: 2021-2023

Funding: Cerebral Palsy Alliance

Chief Investigators: Wixey J, Colditz P, Bjorkman ST, Chand K, Patel J, Khosrotehrani K.

Fetal growth restriction (FGR) occurs when a baby fails to grow normally due to receiving inadequate nutrients while developing in the womb. Brain damage in these babies leads to life-long disabilities and up to a 30-fold risk in developing cerebral palsy (CP). Currently there is no treatment available to protect the FGR newborn brain and therefore prevent or even reduce CP in these babies. While the development of strategies to reduce brain deficits in FGR newborns have been proposed as in need of urgent research for several years, very few trials have been undertaken. Assessing long-term outcomes and thorough safety profiling of any treatment is necessary prior to administering therapies to vulnerable newborns.

This project will assess the safety, efficacy, and long-term outcomes of two treatments to protect the FGR brain – placental stem cells and ibuprofen.

Project members

Dr Julie Wixey

Research Fellow
UQ Centre for Clinical Research

Professor Paul Colditz

Deputy Director & Affiliate Professor
UQ Centre for Clinical Research
Director
Perinatal Research Centre
Group Head, Clinical Neurosciences Laboratory
Head of School
School of Clinical Medicine

Dr Tracey Bjorkman

Senior Research Fellow
UQ Centre for Clinical Research
Affiliate Snr Research Fellow
School of Biomedical Sciences
Centre Manager
Centre for Health Services Research

Dr Kirat Chand

Postdoctoral Research Fellow
UQ Centre for Clinical Research